Category: Legislative

U.S. Rep. Bruce Westerman (R-Ark.) has reintroduced a comprehensive health care bill he sponsored during the last session of Congress that would create new reporting requirements for 340B disproportionate share (DSH), children’s, and free-standing cancer hospitals and their child sites.

Elise Stefanik (R-N.Y.), U.S. congresswoman for the 21^st district in upstate New York and third highest-ranking Republican in the House of Representatives, visited independently-owned Condo Pharmacy in Plattsburgh, N.Y., last week in a show of support for the 340B contract pharmacy

President Joe Biden this afternoon is scheduled to sign legislation that for the first time will let Medicare negotiate the prices of certain costly prescription drugs and require drug makers to pay Medicare rebates when their prices outpace inflation. 

House

The U.S. Senate Appropriations Committee wants federal healthcare officials to tell it what they have done about drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

The committee included the directive to the U.S. Health Resources and

The U.S. Senate on Sunday rejected a Republican amendment to Democratic drug pricing and climate change legislation that would have required federally qualified health centers to make insulin and injectable epinephrine available to patients at or below 340B price.

But

The U.S. Senate on Sunday passed historic legislation to let Medicare negotiate the prices of a small number of costly medicines and require drug manufacturers to pay Medicare rebates when prices paid by Medicare rise faster than inflation.

Language in

About 100 safety-net provider advocates marched and chanted yesterday on the grounds of the U.S. Capitol to raise awareness in Congress and beyond about threats to the 340B drug pricing program.

The demonstration, organized by Community Voices for 340B (CV340B),

Senate Democrats said yesterday they would know this week whether an updated Senate drug pricing bill meets the criteria for passage via budget reconciliation, which requires just 50 Democratic votes. The bill remains on track for a floor vote before

Congress’ attitude toward the 340B program will likely change in 2023 and 2024 because of November’s midterm election results, 340B Report Publisher and CEO Ted Slafsky predicts in his latest column for Omnicell.

It is customary for the party that